Navigation Links
Arena Pharmaceuticals Enters Into Strategic Agreements for the Manufacture of Pharmaceutical Material, Including Lorcaserin
Date:12/18/2007

SAN DIEGO, Dec. 18 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that it entered into strategic cooperation agreements with Siegfried Ltd., an affiliate of Siegfried Holding AG (SWX: SFZN). The agreements primarily relate to the manufacturing of lorcaserin hydrochloride, which is expected to be necessary for Arena's planned New Drug Application (NDA) submission to the U.S. Food and Drug Administration (FDA) and for commercialization of lorcaserin after regulatory marketing approval. Lorcaserin is Arena's Phase 3 oral drug candidate being developed for the treatment of obesity. Arena expects that this transaction will close on January 8, 2008 and believes that it has the potential to:

-- Reduce manufacturing related risks to the lorcaserin NDA registration

lots and submission of its planned lorcaserin NDA.

-- Secure a long-term supply of lorcaserin active pharmaceutical

ingredient (API).

-- Reduce the overall manufacturing costs for lorcaserin and other Arena

product candidates.

-- Lead to significant future tax benefits, which may result from a

favorable tax ruling Arena received from Switzerland.

The agreements with Siegfried include the following:

-- A long-term supply agreement for Arena's purchase of lorcaserin API at

competitive rates for a period of 15 years after FDA approval.

-- An asset purchase agreement for Arena's purchase of certain finishing

facility assets and technology, including the transfer of certain

equipment, fixtures and real estate assets used in converting API into

tablet form, the expected finished drug product (FDP) of lorcaserin.

Approximately 70 employees that are trained in the operations of the

purchased assets are expected to be transferred from Siegfried to Arena

in connection with the transaction.

-- A contract manufacturing agreement under which Siegfried will pay for a

significant portion of the costs associated with maintaining the

facility. Under this agreement, Siegfried will sub-contract from Arena

services to finish API currently manufactured by Siegfried into final

commercial tablet forms for Siegfried's customers for at least three

years.

-- A services agreement under which Siegfried will provide at its cost

various technical and business services to Arena related to the

operation of the facility.

"The relationship with Siegfried is an important strategic development that supports our efforts to optimize lorcaserin's economic potential," said Jack Lief, Arena's President and Chief Executive Officer. "It also allows us to better proactively manage manufacturing related risks and costs, and may facilitate commercialization with a partner."

The purchase price of the acquired assets is CHF 32 million in cash and approximately 1.5 million shares of Arena common stock. The cash is payable CHF 22 million at closing and CHF 10 million payable in three equal installments in the third, fourth and fifth years after closing. The stock is subject to a lock-up agreement for a period of three years from closing. The agreements with Siegfried are not expected to increase the total lorcaserin pre-launch manufacturing related cash out-flows when compared to the alternative of outsourcing all manufacturing related activities. Arena estimates that substantially the entire purchase price paid to Siegfried will be recouped through reduced manufacturing related costs within one year post launch of lorcaserin.

The agreements, entered into between Arena's Swiss subsidiary, Arena Pharmaceuticals GmbH, and Siegfried, will replace a significant part of Arena's previous plans to outsource manufacturing related activities for lorcaserin. However, Arena will continue to manage manufacturing related risks by working with multiple suppliers for API and the processing of API into FDP. Arena expects to use the acquired assets for the manufacture of other Arena drug candidates for clinical or commercial use. Further, the acquired facility could be a source of commercial product for any lorcaserin commercialization partner.

"This transaction immediately establishes a key supply chain link in our manufacturing process. Given the high regard of Siegfried as a pharmaceutical supplier, including its professional and highly knowledgeable employees, I'm confident we will be able to realize significant benefits from this transaction," commented Paul W. Maffuid, Ph.D., Arena's Vice President, Pharmaceutical Development.

Siegfried has over 130 years of pharmaceutical and chemical manufacturing experience and its facilities are approved by the United States, Swiss and other European regulatory authorities to produce API and FDP for these markets. The finishing facility assets being acquired by Arena are located in Zofingen, Switzerland and are situated within Siegfried's campus where it also manufactures API. The finishing facility assets are GMP compliant and capable of producing large scale quantities of lorcaserin and other Arena drug candidates for use in clinical trials or commercially if approved for marketing.

About Arena Pharmaceuticals

Arena is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs in four major therapeutic areas: cardiovascular, central nervous system, inflammatory and metabolic diseases. Arena's most advanced drug candidate, lorcaserin, is being investigated in a Phase 3 clinical trial program for the treatment of obesity. Arena's broad pipeline of novel compounds targeting G protein-coupled receptors, an important class of validated drug targets, includes compounds being evaluated independently and with its partners, Merck & Co., Inc. and Ortho-McNeil Pharmaceutical, Inc.

Arena Pharmaceuticals(R) and Arena(R) are registered service marks of the company. "APD" is an abbreviation for Arena Pharmaceuticals Development.

About Siegfried

Active in Life Science markets, the Siegfried Group is a global manufacturer of pharmaceutical products. With production facilities located in Switzerland, Germany, Malta and the United States Siegfried currently has approximately 950 employees and achieved annual sales of approximately CHF 300 million in 2006.

Siegfried integrates two pharmaceutical divisions. Siegfried Actives develops and produces both exclusive active pharmaceutical ingredients (API) and cGMP and non cGMP intermediates for the pharmaceutical industry as well as standard APIs. Siegfried Generics produces generic products.

Siegfried Holding AG is listed on the Swiss Exchange in Zurich (SWX: SFZN).

Forward-Looking Statements

Many statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements about lorcaserin's development, FDA submission and commercialization; the cost savings, efficiencies, reductions in risk, potential tax and other benefits, and expectations relating to the agreements and relationship with Siegfried, including the anticipated activities thereunder, the transfer of employees, the potential for partnering lorcaserin and the use of the acquired assets in connection with a lorcaserin partnership; use of multiple suppliers; the breadth of Arena's pipeline; Arena's strategy, preclinical and internal and partnered clinical programs; and about Arena's ability to develop compounds and commercialize drugs and other statements that are not historical facts. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, Arena's ability to operate the acquired assets, Arena's planned clinical trials and studies may not proceed at the time or in the manner Arena expects or at all, the results of preclinical studies or clinical trials may not be predictive of future results, Arena's ability to partner lorcaserin, APD125, APD791 or other of its compounds or programs, the timing, success and cost of Arena's research, out-licensing endeavors and clinical trials, Arena's ability to obtain additional financing, Arena's ability to obtain and defend its patents, and the timing and receipt of payments and fees, if any, from Arena's collaborators. Additional factors that could cause actual results to differ materially from those stated or implied by Arena's forward-looking statements are disclosed in Arena's filings with the Securities and Exchange Commission. These forward-looking statements represent Arena's judgment as of the time of this release. Arena disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.

Contacts: Jack Lief Mary Claire Duch

President and CEO WeissComm Partners

Media Relations

David Walsey 212.301.7228

Director, Corporate Communications

Arena Pharmaceuticals, Inc.

858.453.7200, ext. 1682

http://www.arenapharm.com


'/>"/>
SOURCE Arena Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Arena Pharmaceuticals to Present at the Bear Stearns 20th Annual Healthcare Conference
2. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiogaphic Data Safety Monitoring Board Review
3. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiographic Data Safety Monitoring Board Review
4. Arena Pharmaceuticals Selected to Join New NASDAQ NeuroInsights Neurotech Index
5. Arena Pharmaceuticals to Present at Two Upcoming Investor Conferences
6. Arena Pharmaceuticals to Report Third Quarter 2007 Financial Results and to Host Conference Call and Webcast on Wednesday, October 17, 2007
7. Arena Pharmaceuticals Announces Third Quarter 2007 Financial Results
8. Arena Pharmaceuticals to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Arena Pharmaceuticals Appoints Phillip M. Schneider and Randall E. Woods to Board of Directors
10. Arena Pharmaceuticals Initiates Second and Third Pivotal Trials Evaluating Lorcaserin for the Treatment of Obesity
11. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... ... 2016 , ... Morris Midwest ( http://www.morrismidwest.com ), a division ... its Maple Grove, Minnesota technical center, May 11-12. The event will feature ... 20 leading suppliers of tooling, accessories, software and other related technology will participate ...
(Date:4/27/2016)... British Columbia , April 27, 2016 /PRNewswire/ ... oder "NanoStruck") (CSE: NSK) (OTCPink: NSKQB) ( ... im Anschluss an ihre Pressemitteilung vom 13. August ... erhalten hat, ihre Finanzen um zusätzliche 200.000.000 Einheiten ... 4.000.000 Kanadische Dollar zu bringen. Davon wurden 157.900.000 ...
(Date:4/27/2016)... ... 2016 , ... A compact PET scanner called NuPET™ has ... Resonance Imaging) in existing third-party MRI systems. PET and MRI are complementary imaging ... Simultaneous PET/MRI imaging offers a solution to many challenges that face researchers who ...
(Date:4/26/2016)... ... April 27, 2016 , ... Cameron Cushman ... as an associate in the firm’s Intellectual Property practice group. , Clients turn ... patent applications. He has an electrical engineering and computer engineering background, and experience ...
Breaking Biology Technology:
(Date:4/28/2016)... , April 28, 2016 First quarter 2016: ... up 966% compared with the first quarter of 2015 ... SEK 589.1 M (loss: 18.8) and the operating margin was 40% ... 0.32) Cash flow from operations was SEK 249.9 M ... revenue guidance is unchanged, SEK 7,000-8,500 M. The operating ...
(Date:4/15/2016)... 2016  A new partnership announced today will ... decisions in a fraction of the time it ... high-value life insurance policies to consumers without requiring ... Force Diagnostics, rapid testing (A1C, Cotinine and HIV) ... pressure, weight, pulse, BMI, and activity data) available ...
(Date:3/31/2016)... RATON, Florida , March 31, 2016 ... LEGX ) ("LegacyXChange" or the "Company") ... for potential users of its soon to be launched ... video ( https://www.youtube.com/channel/UCyTLBzmZogV1y2D6bDkBX5g ) will also provide ... the use of DNA technology to an industry that ...
Breaking Biology News(10 mins):